Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
Martinsried/Munich, April 04, 2023. Medigene AG is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr.... | April 4, 2023
Dolores Schendel Pamela Keck Hongsheng Sciences Therapy Development Prime Standard Chief Scientific Officer
Source: marketscreener.com